

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	1338731
<b>Application Number:</b>	10598854
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	1320
<b>Title of Invention:</b>	Crystalline and Amorphous Forms of Efavoxiral Sodium
<b>First Named Inventor/Applicant Name:</b>	Douglas G. Johnson
<b>Customer Number:</b>	25871
<b>Filer:</b>	Mary Breen Smith.
<b>Filer Authorized By:</b>	
<b>Attorney Docket Number:</b>	ALL.06/PCT-US
<b>Receipt Date:</b>	29-NOV-2006
<b>Filing Date:</b>	
<b>Time Stamp:</b>	12:37:53
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part /.zip	Pages (if appl.)
1	Foreign Reference	DE02432560A1.pdf	860043	no	21

### Warnings:

<b>Information:</b>					
2	Foreign Reference	WO09734594A2.pdf	2347384	no	83
<b>Warnings:</b>					
<b>Information:</b>					
3	Foreign Reference	WO00114316A1.pdf	3114388	no	97
<b>Warnings:</b>					
<b>Information:</b>					
4	Foreign Reference	WO03086324A2.pdf	1508307	no	29
<b>Warnings:</b>					
<b>Information:</b>					
5	Foreign Reference	WO3092700.pdf	4217184	no	94
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	Abraham_1992_Biochem_31.pdf	1051813	no	9
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	Abraham_1998_Med_Chem_Res_8.pdf	397487	no	9
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	Amorino_2001_Radiation_Res_156.pdf	454766	no	7
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	Chang_and_Lo_2003_The_Oncologist_8.pdf	1263594	no	13
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	Grella_2000_J_Med_Chem_43.pdf	1428671	no	12
<b>Warnings:</b>					

<b>Information:</b>					
11	NPL Documents	Kavanagh_2001_Int_J_Radiat_Oncol_Biol_Phys_49.pdf	628780	no	7
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	Mugurma_et_al_July_1999_LC_GC_International.pdf	285555	no	4
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	PageI_1998_J_Pharmacol_Exp_Thera_285.pdf	926691	no	8
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	Papassotiriou_1998_Experimental_Hematology_v26_p922.pdf	442955	no	5
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	Randad_1991_J_Med_Chem_34.pdf	530723	no	6
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	Rockwell_1998_Rad_Oncol_Invest_6.pdf	775236	no	10
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	Rowinsky_1999_Oncology_v10_p61.pdf	1223811	no	10
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	Safo_2001_Protein_Sci_10.pdf	693910	no	7
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	Sarrafi_Yazdi_1999_Brain_Res_826_172.pdf	923299	no	9
<b>Warnings:</b>					

<b>Information:</b>					
20	NPL Documents	Steffen_1998_Oxygen_Transp_Tissue_XX_p653.pdf	942164	no	9
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	Steffen_2003_Advances_in_Exp_v530_p249.pdf	719944	no	11
<b>Warnings:</b>					
<b>Information:</b>					
22	NPL Documents	Teicher_1998_Cancer_Chemotherapy_Pharmacol_42_24.pdf	753445	no	7
<b>Warnings:</b>					
<b>Information:</b>					
23	NPL Documents	Wahr_2001_Anesth_Analg_92_615.pdf	651827	no	6
<b>Warnings:</b>					
<b>Information:</b>					
24	NPL Documents	Watson_1997_Stroke_28_1624.pdf	846334	no	7
<b>Warnings:</b>					
<b>Information:</b>					
25	NPL Documents	Teicher_1996_Drug_Dev_Res_38_1.pdf	976184	no	11
<b>Warnings:</b>					
<b>Information:</b>					
26	NPL Documents	Wireko_1991_J_Med_Chem_34_758.pdf	970145	no	10
<b>Warnings:</b>					
<b>Information:</b>					
27	Information Disclosure Statement (IDS) Filed	_IDS.pdf	141963	no	3
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
<b>Total Files Size (in bytes):</b>			29076603		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.